The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | The effect of CXCR4 inhibition on malignant cells
Lilach Moyal, PhD, Tel Aviv University, Tel Aviv, Israel, talks on CXCR4 and its potential role as a therapeutic target in mycosis fungoides (MF). CXCR4 is a G-protein coupled chemokine receptor playing a role in cell survival that is overexpressed in many solid and liquid tumors, including MF. Experiments showed that inhibition of this receptor led to inactivation of the MAPK and PI3K downstream signaling cascades involved in chemotaxis, apoptosis and survival, thus highlighting the potential of using a CXCR4 inhibitor in the context of MF. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
